Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended Current Report on Form 8-K/A with the U.S. Securities and Exchange Commission on June 27, 2024. The report provides updates on the financial impact of the previously announced Spin-Off of certain business activities. Illumina has concluded its impairment testing and estimates a goodwill impairment charge of $1,466 million for the second quarter of 2024, which represents the full remaining carrying value of goodwill related to its GRAIL business as of March 31, 2024. Additionally, the company anticipates a $420 million impairment charge for the in-process research and development (IPR&D) intangible asset of GRAIL. These charges are not expected to result in any significant future cash expenditures and will be excluded from Illumina's non-GAAP financial metrics.

Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended Current Report on Form 8-K/A with the U.S. Securities and Exchange Commission on June 27, 2024. The report provides updates on the financial impact of the previously announced Spin-Off of certain business activities. Illumina has concluded its impairment testing and estimates a goodwill impairment charge of $1,466 million for the second quarter of 2024, which represents the full remaining carrying value of goodwill related to its GRAIL business as of March 31, 2024. Additionally, the company anticipates a $420 million impairment charge for the in-process research and development (IPR&D) intangible asset of GRAIL. These charges are not expected to result in any significant future cash expenditures and will be excluded from Illumina's non-GAAP financial metrics.